PlantEXT Ltd.

PlantEXT Ltd., founded in 2015 and headquartered in Canada, is carving a niche in the Biopharma, Biotechnology, Life Sciences, and Pharmaceutical industries by developing cannabis-based anti-inflammatory products. With operations rooted in both Canada and Israel, PlantEXT leverages the expertise of top R&D and product commercialization experts to create science-backed medical cannabis solutions.

The company is notable for its pioneering formulations that target inflammation-related conditions, supported by clinical studies. PlantEXT focuses on delivering high-margin, fast-to-market products, emphasizing treatments for dermatological diseases and complex conditions like COVID-19-induced lung inflammation and Inflammatory Bowel Disease. Their strategic license agreement with the Government of the State of Israel underscores their access to exclusive global commercialization rights for innovative IP.

Though the company has yet to indicate its last funding round or investors, its collaborations, particularly in the realm of the endocannabinoid system for addiction treatment, position PlantEXT as a promising player in the medical cannabis sector. Investors considering PlantEXT are advised that its strategy rests on a solid scientific foundation with significant commercialization potential.